New hope for ALS: major trial tests drug to slow devastating disease
NCT ID NCT04057898
First seen Nov 01, 2025 · Last updated Apr 10, 2026 · Updated 19 times
Summary
This study is testing whether an oral drug called Ibudilast (MN-166) can slow the progression of ALS (amyotrophic lateral sclerosis or Lou Gehrig's disease). About 234 adults recently diagnosed with ALS will take either the drug or a placebo for 12 months, followed by an option for everyone to receive the drug for 6 more months. The main goal is to see if the drug helps people maintain their physical abilities and live longer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Augusta University
Augusta, Georgia, 30912, United States
-
Duke University
Durham, North Carolina, 27705, United States
-
Hennepin Healthcare Research Institute
Minneapolis, Minnesota, 55415, United States
-
Hopital de L'Enfant-Jesus, CHU de Quebec-Universite Laval
Québec, G1J 1Z4, Canada
-
Indiana University IU Health Neuroscience Center
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University
Baltimore, Maryland, 21287, United States
-
Lehigh Valley Health Network
Allentown, Pennsylvania, 18103, United States
-
Mayo Clinic
Jacksonville, Florida, 32224, United States
-
McMaster University Medical Center
Hamilton, Ontario, L8N 3Z5, Canada
-
Montreal Neurological Institute and Hospital
Montreal, Quebec, H3A 2B4, Canada
-
SUNY Upstate Medical University
Syracuse, New York, 13210, United States
-
Sunnybrook Research Institute
Toronto, Ontario, M4N 3M5, Canada
-
University of Alberta Hospital
Edmonton, Alberta, T6G 2G3, Canada
-
University of California
Orange, California, 92868, United States
-
University of Saskatchewan - Sastakoon Hospital
Saskatoon, Saskatchwean, S7K 0M7, Canada
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
Conditions
Explore the condition pages connected to this study.